A TGF-βR2 inhibitor (LY2109761) was then used to inhibit ALG2 overexpressing breast cancer cell lines which induced apoptosis post-radiotherapy and diminished tumorsphere formation as well as CD44+/CD24− CSCs [79]. The gene discussed is CD44; the disease is breast carcinoma.